Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications

被引:58
|
作者
Faulkner, Guy
Cohn, Tony A.
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M6J 1H4, Canada
[2] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
schizophrenia; antipsychotic medication; weight management; metabolic disturbance; intervention; review;
D O I
10.1177/070674370605100805
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives: To provide an overview of pharmacologic and nonpharmacologic strategies for antipsychotic-associated weight gain and metabolic disturbance, to identify important areas for future research, and to make practice recommendations based on current knowledge. Methods: We undertook a selective review of interventions for weight gain and metabolic disturbance in the general population and in individuals treated with antipsychotic medications, focusing on randomized controlled trials in schizophrenia. Results: Pharmacologic strategies include medication choice, medication dosage and formulation, choice of concomitant psychotropic medications, medication switching, medication addition to effect weight loss or prevent weight gain, and medications to increase insulin sensitivity. Medication choice and medication switching may have the most potent influence on weight and metabolic parameters. Modest short-term weight loss can occur with the addition of selective medications and (or) lifestyle interventions. However, more rigorous and longer-term studies are needed. Conclusions: Although difficult, the prevention of weight gain and the promotion of weight loss are possible for individuals treated with antipsychotic medications. Further research, including diabetes prevention studies, is required. We suggest a pathway for the management of weight gain and emerging metabolic disturbance.
引用
下载
收藏
页码:502 / 511
页数:10
相关论文
共 50 条
  • [1] Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications (vol 51, pg 502, 2006)
    Faulkner, Guy
    Cohn, Tony A.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (09): : 620 - 620
  • [2] STRATEGIES TO MANAGE WEIGHT GAIN IN PEOPLE TREATED WITH ANTIPSYCHOTIC MEDICATIONS
    Mohiuddin, S. M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2015, 49 : 115 - 115
  • [3] Nonpharmacologic and pharmacologic management of weight gain
    Greenberg, I
    Chan, S
    Blackburn, GL
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 31 - 36
  • [4] Metabolic monitoring for patients treated with antipsychotic medications
    Cohn, Tony A.
    Sernyak, Michael J.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (08): : 492 - 501
  • [5] Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
    Maayan, Lawrence
    Correll, Christoph U.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (06) : 517 - 535
  • [6] Genetics of weight gain associated with antipsychotic medications
    Mueller, D. J.
    Peter, C.
    Puls, I.
    Brandl, E. J.
    Lang, U. E.
    Gallinat, J.
    Heinz, A.
    NERVENARZT, 2009, 80 (05): : 556 - 563
  • [7] Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
    Jaberi, Nayyer
    Faramarzi, Elnar
    Farahbakhsh, Mostafa
    Ostadarahimi, Alireza
    Jafarabadi, Mohammad Asghari
    Fakhari, Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2020, 11 (03) : 310 - 314
  • [8] Weight gain in antipsychotic naive patients and metabolic side effects
    Tarricone, I
    Gozzi, Ferrari B.
    Berardi, D.
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2010, 68 (06) : 668 - 669
  • [9] Weight gain with clozapine as compared to conventional antipsychotic medications
    Covell, NH
    Essock, SM
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 354 - 354
  • [10] Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia
    Marteene, Wade
    Winckel, Karl
    Hollingworth, Sam
    Kisely, Steve
    Gallagher, Erin
    Hahn, Margaret
    Ebdrup, Bjorn H.
    Firth, Joseph
    Siskind, Dan
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (12) : 1149 - 1160